Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Crinetics Pharmaceuticals Inc CRNX

Healthcare Biotechnology
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid... see more

Recent & Breaking News (NDAQ:CRNX)

Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

GlobeNewswire September 25, 2019

Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire September 3, 2019

Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2019

Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism

GlobeNewswire July 29, 2019

Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors

GlobeNewswire July 16, 2019

Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2019

Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly

GlobeNewswire March 19, 2019

Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning

GlobeNewswire March 18, 2019

Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019

GlobeNewswire March 14, 2019

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

GlobeNewswire March 13, 2019

Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

GlobeNewswire February 21, 2019

Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2019

New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 21, 2018

Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference

GlobeNewswire November 20, 2018

Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2018

Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology

GlobeNewswire September 26, 2018

Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire August 30, 2018

Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire July 20, 2018

Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

GlobeNewswire July 17, 2018